<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0001-6002</journal-id>
<journal-title><![CDATA[Acta Médica Costarricense]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. costarric]]></abbrev-journal-title>
<issn>0001-6002</issn>
<publisher>
<publisher-name><![CDATA[Colegio de Médicos y Cirujanos de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0001-60022020000400175</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización de prematuros ingresados por bronquiolitis en el Hospital Nacional de Niños]]></article-title>
<article-title xml:lang="en"><![CDATA[Characterization of premature patients admitted for bronchiolitis at the National Children&#8217;s Hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madriz-Vargas]]></surname>
<given-names><![CDATA[Georgina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ávila De Benedictis]]></surname>
<given-names><![CDATA[Lydiana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,aff1  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Caja Costarricense de Seguro Social. Hospital Nacional de Niños &#8220;Dr. Carlos Sáenz Herrera&#8221;, Departamento de Medicina]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>62</volume>
<numero>4</numero>
<fpage>175</fpage>
<lpage>180</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0001-60022020000400175&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0001-60022020000400175&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0001-60022020000400175&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La bronquiolitis es la infección del tracto respiratorio inferior más frecuente en lactantes. El virus respiratorio sincicial es el principal agente y responde hasta por un 85 % de los casos. Los principales factores de riesgo asociados son: sexo masculino; lactantes menores; prematuros; patologías médicas de fondo como: cardiopatía congénita, displasia broncopulmonar, síndrome de Down y enfermedades neuromusculares; así como otros factores ambientales y sociales. El objetivo de este estudio fue caracterizar los prematuros, el tratamiento utilizado, el perfil de la inmunofluorescencia viral, las complicaciones, el uso de palivizumab y los costos de hospitalización en pacientes hospitalizados por bronquiolitis durante enero de 2011 y diciembre de 2011.  Pacientes y métodos:  Estudio observacional, descriptivo, basado en la revisión retrospectiva de expedientes clínicos de una serie de pacientes hospitalizados en el Hospital Nacional de Niños de la Caja Costarricense de Seguro Social. Se incluyeron todos los pacientes menores de 2 años egresados con el diagnóstico de bronquiolitis durante 2011, con el antecedente de prematuridad (menor de 37 semanas de edad gestacional).  Resultados:  Se incluyó un total de 141 pacientes; un 63 % (n=89) de sexo masculino, promedio de edad 5,7 meses (rango 0-24). Un 43 % (n=61) de los pacientes manifestó bronquiolitis antes de los 3 meses de edad. Con respecto a la edad gestacional, se obtuvo que el 35,46 % de los pacientes eran de 32 a 35 semanas, de 35 a 37 semanas un 31,2 %, de 30 a 32 semanas un 19,86 % y el resto menores de las 29 semanas. En 93 niños (66 %) se anotó el antecedente de tabaquismo en el entorno del hogar; de forma específica, en 17 % de estos pacientes se presentó el antecedente de tabaquismo pasivo, al reportarse que el padre o el abuelo eran los fumadores activos. El antecedente heredofamiliar de asma fue positivo en el 41,8 %. Con respecto al tratamiento recibido durante su hospitalización, el 100 % ameritó oxígeno suplementario y un 61 % recibió nebulizaciones con salbutamol; los esteroides sistémicos se utilizaron en el 33 % de los pacientes y solo en un 29 % se utilizó la terapia antibiótica. Un 28 % de la población estudiada presentó complicaciones, de los cuales 28 (19,86 %) prematuros ameritaron soporte ventilatorio. El hallazgo de atelectasia en la radiografía de tórax se evidenció en el 7,8 % de los pacientes. Únicamente un 4,25 % de los pacientes tuvo una sobreinfección bacteriana. Debido a la dificultad de los accesos venosos de este grupo de niños, 14 (9,93 %) ameritaron la colocación de catéter venoso central. El rango de estancia hospitalaria fue de 1 a 31 días, con un promedio de 7; la hospitalización en la Unidad de Cuidados Intensivos alcanzó un rango de 5 a 18 días, con un promedio de 10, y el promedio de la necesidad de ventilación mecánica asistida fue de 8,2 días, y de cánula de alto flujo de 2,8 días. Únicamente un 6,38 % (n=9) tenía el antecedente de haber recibido profilaxis con palivizumab: la mayoría había recibido más de dos dosis y ninguno de los pacientes había completado el esquema de las 5 dosis. Durante 2011, el Hospital reportó que el costo promedio diario fue de ¢ 766 476. Con un total de 1001 días de hospitalización acumulada, se estimó un costo directo de ¢ 767 242 142, equivalente a $ 1 522 306 (dólares estadounidenses).  Conclusión:  El perfil de los prematuros en este estudio es muy similar a lo reportado internacionalmente, por ser un grupo de prematuros con prevalencia más elevada de complicaciones que la población pediátrica general. Dado el costo que implica el internamiento de estos pacientes, es necesario evaluar la aplicación de intervenciones como el palivizumab para prevenir la hospitalización y disminuir otros costos al sistema de salud solidario.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Bronchiolitis is the most common lower respiratory tract infection in infants. Respiratory Syncytial Virus is the main agent and responds in up to 85% of cases. The main associated risk factors are: male sex, young infants, premature infants, underlying medical conditions such as: congenital heart disease, bronchopulmonary dysplasia, Down syndrome and neuromuscular diseases; as well as other environmental and social factors. The objective of this study was to characterize preterm infants, the treatment used, the viral immunofluorescence profile, complications, the use of palivizumab, and hospitalization costs in patients hospitalized for bronchiolitis during January 2011 and December 2011.  Methods:  An observational, descriptive study, based on a retrospective review of clinical records of a series of hospitalized patients at the National Children&#8217;s Hospital (HNN) of the Costa Rican Social Security Fund. All patients under 2 years of age who were discharged with a diagnosis of bronchiolitis during 2011, with a history of prematurity (less than 37 weeks gestational age) were included.  Results:  A total of 141 patients were included, 63% (n = 89) were male, with an average age of 5.7 months (range 0-24). 43% (n = 61) of patients with Bronchiolitis manifested before 3 months of age. With regard to gestational age, it was found that 35.46% of the patients were between 32 and 35 weeks, 31.2% from 35 to 37 weeks, 19.86% from 30 to 32 weeks and the rest were under 29 weeks. In 93 children (66%) a history of smoking was noted in the home environment; specifically, 17% of these patients had a history of passive smoking as the father or grandfather was reported as active smokers. In relation to the hereditary family history of asthma, it was positive in 41.8%. Regarding the treatment received during their hospitalization, 100% required supplemental oxygen and 61% received nebulizations with salbutamol; systemic steroids were used in 33% of patients and antibiotic therapy was used in only 29%. 28% of the population studied presented complications, of which 28 (19.86%) premature babies required ventilatory support. The finding of atelectasis on the chest X-ray occurred in 7.8% of the patients. Only 4.25% of the patients had a bacterial superinfection. Due to the difficulty of the venous access in this group of children, 14 (9.93%) of them required the placement of a central venous catheter. The range of hospital stay was from 1 to 31 days with an average of 7 days, hospitalization in the Intensive Care Unit reached a range of 5 to 18 days with an average of 10 days and the average need for assisted mechanical ventilation It was 8.2 days and the high-flow cannula was 2.8 days. Only 6.38% (n = 9) had a history of having received prophylaxis with Palivizumab, the majority had received more than two doses, and none of the patients had completed the 5-dose schedule. During that year 2011, the hospital reported that the average daily cost was ¢ 766 476; With a total of 1001 cumulative hospitalization days, a total direct cost of ¢ 767 242 142 was estimated, equivalent to $ 1 522 306 (US dollars).  Conclusion:  The profile of the characteristics of premature infants in this study is very similar to that reported internationally, as it is a group of premature infants with a higher prevalence of complications than the general pediatric population. Given the cost involved in the hospitalization of these patients, it is necessary to evaluate the application of interventions such as palivizumab to prevent hospitalization and reduce other costs to the solidarity health system.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[bronquiolitis]]></kwd>
<kwd lng="es"><![CDATA[virus respiratorio sincicial]]></kwd>
<kwd lng="es"><![CDATA[prematuridad]]></kwd>
<kwd lng="es"><![CDATA[palivizumab]]></kwd>
<kwd lng="es"><![CDATA[lactantes]]></kwd>
<kwd lng="es"><![CDATA[prematuros]]></kwd>
<kwd lng="en"><![CDATA[bronchiolitis]]></kwd>
<kwd lng="en"><![CDATA[respiratory syncytyial virus]]></kwd>
<kwd lng="en"><![CDATA[prematurity]]></kwd>
<kwd lng="en"><![CDATA[palivizumab]]></kwd>
<kwd lng="en"><![CDATA[infants]]></kwd>
<kwd lng="en"><![CDATA[premature]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ávila]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yock-Corrales]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Solís]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hoepker]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización del abordaje y manejo del paciente con bronquiolitis en Costa Rica.]]></article-title>
<source><![CDATA[Acta Pedi Costarric]]></source>
<year>2010</year>
<volume>22</volume>
<page-range>104-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ralston]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Lieberthal]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Meissner]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Alverson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Baley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gadomski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis.]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2014</year>
<volume>134</volume>
<page-range>e1474-502</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute bronchiolitis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2007</year>
<volume>335</volume>
<page-range>1037-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zorc]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Breese]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronchiolitis: Recent evidence on diagnosis and management]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2010</year>
<volume>125</volume>
<page-range>342-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cody Meissner]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Viral bronchiolitis in children]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campuzano]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronquitis y bronquiolitis]]></article-title>
<source><![CDATA[Pediatr Integral]]></source>
<year>2012</year>
<volume>16</volume>
<page-range>37-44</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visscher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Myers]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronchiolitis.]]></article-title>
<source><![CDATA[Proc Am Thorac Soc]]></source>
<year>2006</year>
<volume>3</volume>
<page-range>41-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Claire]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute viral bronchiolitis in children- a very common condition with few options.]]></article-title>
<source><![CDATA[Paediatr Respir Rev.]]></source>
<year>2010</year>
<volume>11</volume>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García García]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Korta Murua]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Callejón Callejón]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronquiolitis agudaviral]]></article-title>
<source><![CDATA[Protoc diagn ter pediatr]]></source>
<year>2017</year>
<volume>1</volume>
<page-range>85-102</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa-Sangradora]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González de Dios]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grupo de revisión del proyecto abreviado (Bronquiolitis-estudio de variabilidad, idoneidad y adecuación). Conferencia de Consenso sobre bronquiolitis aguda (II): epidemiología de la bronquiolitis aguda. Revisión de la evidencia cientí&#64257;ca.]]></article-title>
<source><![CDATA[An Pediatr]]></source>
<year>2010</year>
<volume>72</volume>
<page-range>222</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pannell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality in children from influenza and respiratory syncytial virus.]]></article-title>
<source><![CDATA[J Epidemiol Community Health]]></source>
<year>2005</year>
<volume>59</volume>
<page-range>586-90</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meerhoff]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Paget]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kimpen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schellevis]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variation of respiratory syncytial virus and the relation with meteorological factors in different winter seasons]]></article-title>
<source><![CDATA[Pediatr Infect Dis J]]></source>
<year>2009</year>
<volume>28</volume>
<page-range>860-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ralston]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2009</year>
<volume>155</volume>
<page-range>728-33</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gadomski]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Brower]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cochrane database of systematic reviews]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bialy]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vandermeer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tjosvold]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Plint]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane database of systematic.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grupo de revisión del proyecto abreviado (Bronquiolitis- estudio de variabilidad, idoneidad y adecuación). Conferencia de Consenso sobre bronquiolitis aguda (V): prevención de la bronquiolitis aguda.]]></article-title>
<source><![CDATA[Revisión de la evidencia cientí&#64257;ca. An Pediatr (Barc).]]></source>
<year>2010</year>
<volume>72</volume>
<numero>353</numero>
<issue>353</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Diez-Delgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ortega]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Batles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antecedentes perinatales y hospitalización por bronquiolitis. Comparación con el Impact-RSV Study Group.]]></article-title>
<source><![CDATA[An Esp Pediatr]]></source>
<year>2000</year>
<volume>53</volume>
<page-range>527-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grupo de revisión del proyecto abreviado (Bronquiolitis- estudio de variabilidad, idoneidad y adecuación). Conferencia de Consenso sobre bronquiolitis aguda (VI): pronóstico en la bronquiolitis aguda.]]></article-title>
<source><![CDATA[Revisión de la evidencia cientí&#64257;ca. An Pediatr (Barc).]]></source>
<year>2010</year>
<volume>72</volume>
<numero>354</numero>
<issue>354</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawson-Caswell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muncie]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respiratory syncytial sirus Infection in children.]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2011</year>
<volume>83</volume>
<page-range>141-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Checchia]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and management of severe respiratory syncytial virus]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<page-range>S7-S12</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weisman]]></surname>
<given-names><![CDATA[LE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions]]></article-title>
<source><![CDATA[Pediatr Infect Dis J.]]></source>
<year>2003</year>
<volume>22</volume>
<page-range>S33-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seiden]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Scarfone]]></surname>
<given-names><![CDATA[RJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronchiolitis: An evidence-based approach to management]]></article-title>
<source><![CDATA[Clin Ped Emerg Med]]></source>
<year>2009</year>
<volume>10</volume>
<page-range>75-81</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alansari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sakran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[El Sayyed]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mahjoub]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nebulized 5% or 3% Hypertonic or 0.9% Saline for treating Acute Bronchiolitis in infants.]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2010</year>
<volume>157</volume>
<page-range>630-4</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Onoro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Teresa]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bronquiolitis grave. Cambios epidemiológicos y de soporte respiratorio]]></article-title>
<source><![CDATA[An Pediatr (Barc).]]></source>
<year>2011</year>
<volume>74</volume>
<page-range>371-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<collab>Commitee on Infectious Diseases.</collab>
<article-title xml:lang=""><![CDATA[Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2009</year>
<volume>124</volume>
<page-range>1694-701</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feltes]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Cabalka]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Meissner]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Piazza]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carlin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Top]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in Young children with hemodynamically significant congenital heart disease]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2003</year>
<volume>143</volume>
<page-range>532-40</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<collab>The IMpact-RSV Study Group.</collab>
<article-title xml:lang=""><![CDATA[Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>1998</year>
<volume>102</volume>
<page-range>531-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soto-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soto-Quirós]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología del asma en Costa Rica.]]></article-title>
<source><![CDATA[Rev Méd Hosp Nac Niños]]></source>
<year>2004</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-53</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
